PortfoliosLab logoPortfoliosLab logo
REAX vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

REAX vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Real Brokerage Inc (REAX) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, REAX achieves a -52.88% return, which is significantly lower than NVO's -12.70% return.


REAX

1D
-5.49%
1M
-19.25%
YTD
-52.88%
6M
-54.50%
1Y
-59.72%
3Y*
10.64%
5Y*
10Y*

NVO

1D
-2.61%
1M
-2.19%
YTD
-12.70%
6M
-6.35%
1Y
-38.32%
3Y*
-16.12%
5Y*
3.67%
10Y*
6.45%
*Multi-year figures are annualized to reflect compound growth (CAGR)

REAX vs. NVO - Yearly Performance Comparison


2026 (YTD)20252024202320222021
REAX
Real Brokerage Inc
-52.88%-20.65%187.50%52.38%-71.54%-63.10%
NVO
Novo Nordisk A/S
-12.70%-39.22%-15.93%54.84%22.66%33.16%

Correlation

The correlation between REAX and NVO is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.17

Correlation (All Time)
Calculated using the full available price history since Jun 16, 2021

0.13

Fundamentals

Market Cap

REAX:

$384.74M

NVO:

$190.94B

EPS

REAX:

-$0.03

NVO:

$27.42

PS Ratio

REAX:

0.19

NVO:

0.58

PB Ratio

REAX:

5.86

NVO:

0.94

Total Revenue (TTM)

REAX:

$2.08B

NVO:

$327.80B

Gross Profit (TTM)

REAX:

$173.33M

NVO:

$268.30B

EBITDA (TTM)

REAX:

-$4.17M

NVO:

$181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

REAX vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REAX
REAX Risk / Return Rank: 55
Overall Rank
REAX Sharpe Ratio Rank: 44
Sharpe Ratio Rank
REAX Sortino Ratio Rank: 44
Sortino Ratio Rank
REAX Omega Ratio Rank: 55
Omega Ratio Rank
REAX Calmar Ratio Rank: 88
Calmar Ratio Rank
REAX Martin Ratio Rank: 44
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 1414
Overall Rank
NVO Sharpe Ratio Rank: 1010
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 1313
Sortino Ratio Rank
NVO Omega Ratio Rank: 1111
Omega Ratio Rank
NVO Calmar Ratio Rank: 1515
Calmar Ratio Rank
NVO Martin Ratio Rank: 2020
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

REAX vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Real Brokerage Inc (REAX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


REAXNVODifference

Sharpe ratio

Return per unit of total volatility

-1.05

-0.74

-0.31

Sortino ratio

Return per unit of downside risk

-1.68

-0.85

-0.83

Omega ratio

Gain probability vs. loss probability

0.80

0.88

-0.08

Calmar ratio

Return relative to maximum drawdown

-0.85

-0.68

-0.18

Martin ratio

Return relative to average drawdown

-1.60

-1.01

-0.58

REAX vs. NVO - Sharpe Ratio Comparison

The current REAX Sharpe Ratio is -1.05, which is lower than the NVO Sharpe Ratio of -0.74. The chart below compares the historical Sharpe Ratios of REAX and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


REAXNVODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-1.05

-0.74

-0.31

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.10

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.20

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.42

0.47

-0.89

Drawdowns

REAX vs. NVO - Drawdown Comparison

The maximum REAX drawdown since its inception was -89.60%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for REAX and NVO.


Loading charts...

Drawdown Indicators


REAXNVODifference

Max Drawdown

Largest peak-to-trough decline

-89.60%

-74.70%

-14.90%

Max Drawdown (1Y)

Largest decline over 1 year

-68.40%

-55.03%

-13.37%

Max Drawdown (3Y)

Largest decline over 3 years

-74.47%

-74.70%

+0.23%

Max Drawdown (5Y)

Largest decline over 5 years

-74.70%

Max Drawdown (10Y)

Largest decline over 10 years

-74.70%

Current Drawdown

Current decline from peak

-82.80%

-68.81%

-13.99%

Average Drawdown

Average peak-to-trough decline

-69.31%

-17.75%

-51.56%

Ulcer Index

Depth and duration of drawdowns from previous peaks

36.51%

36.77%

-0.26%

Volatility

REAX vs. NVO - Volatility Comparison

Real Brokerage Inc (REAX) has a higher volatility of 18.25% compared to Novo Nordisk A/S (NVO) at 7.70%. This indicates that REAX's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


REAXNVODifference

Volatility (1M)

Calculated over the trailing 1-month period

18.25%

7.70%

+10.55%

Volatility (6M)

Calculated over the trailing 6-month period

48.19%

37.81%

+10.38%

Volatility (1Y)

Calculated over the trailing 1-year period

57.13%

51.76%

+5.37%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

71.23%

38.20%

+33.03%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

71.23%

32.49%

+38.74%

Dividends

REAX vs. NVO - Dividend Comparison

REAX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.20%.


PositionTTM20252024202320222021202020192018201720162015
NVO
Novo Nordisk A/S
4.20%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%
REAX
Real Brokerage Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

REAX vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Real Brokerage Inc and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B20222023202420252026
465.55M
96.82B
(REAX) Total Revenue
(NVO) Total Revenue
Values in USD except per share items

REAX vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between Real Brokerage Inc and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
8.9%
86.0%
Portfolio components
REAX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Real Brokerage Inc reported a gross profit of 41.58M and revenue of 465.55M. Therefore, the gross margin over that period was 8.9%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

REAX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Real Brokerage Inc reported an operating income of -3.13M and revenue of 465.55M, resulting in an operating margin of -0.7%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

REAX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Real Brokerage Inc reported a net income of -3.42M and revenue of 465.55M, resulting in a net margin of -0.7%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.


Frequently Asked Questions


REAX and NVO have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

REAX has higher volatility (18.25%) compared to NVO (7.70%). In terms of maximum drawdown, REAX dropped -89.60% vs NVO's -74.70%.

NVO currently has the higher Sharpe Ratio (-0.74 vs -1.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for REAX and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer